Think big, start small: How nanomedicine could alleviate the burden of rare CNS diseases

The complexity and organization of the central nervous system (CNS) is widely modulated by the presence of the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB), which both act as biochemical, dynamic obstacles impeding any type of undesirable exogenous exchanges. The disruption of these barriers is usually associated with the development of neuropathologies which can be the consequence of genetic disorders, local antigenic invasions, or autoimmune diseases. These disorders can take the shape of rare CNS-related diseases (other than Alzheimer\u27s and Parkinson\u27s) which a exhibit relatively low or moderate prevalence and could be part of a potential line of treatments from current nanotargeted therapies. Indeed, one of the most promising therapeutical alternatives in that field comes from the development of nanotechnologies which can be divided between drug delivery systems and diagnostic tools. Unfortunately, the number of studies dedicated to treating these rare diseases using nanotherapeutics is limited, which is mostly due to a lack of interest from industrial pharmaceutical companies. In the present review, we will provide an overview of some of these rare CNS diseases, discuss the physiopathology of these disorders, shed light on how nanotherapies could be of interest as a credible line of treatment, and finally address the major issues which can hinder the development of efficient therapies in that area

Start small : how nanomedicine could alleviate the burden of rare CNS Diseases

The complexity and organization of the central nervous system (CNS) is widely modulated by the presence of the blood–brain barrier (BBB) and the blood–cerebrospinal fluid barrier (BCSFB), which both act as biochemical, dynamic obstacles impeding any type of undesirable exogenous exchanges. The disruption of these barriers is usually associated with the development of neuropathologies which can be the consequence of genetic disorders, local antigenic invasions, or autoimmune diseases. These disorders can take the shape of rare CNS-related diseases (other than Alzheimer’s and Parkinson’s) which a exhibit relatively low or moderate prevalence and could be part of a potential line of treatments from current nanotargeted therapies. Indeed, one of the most promising therapeutical alternatives in that field comes from the development of nanotechnologies which can be divided between drug delivery systems and diagnostic tools. Unfortunately, the number of studies dedicated to treating these rare diseases using nanotherapeutics is limited, which is mostly due to a lack of interest from industrial pharmaceutical companies. In the present review, we will provide an overview of some of these rare CNS diseases, discuss the physiopathology of these disorders, shed light on how nanotherapies could be of interest as a credible line of treatment, and finally address the major issues which can hinder the development of efficient therapies in that area

Release kinetics from nano-inclusion-based and affinity-based hydrogels: A comparative study

In this study, we compare the release mechanisms from nanocomposite hydrogels. Liposomes made of different compositions of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC), nanogels made of chitosan-hyaluronic acid association and crosslinked nanogels made of Nisopropylacrylamide (NIPAM) and different ratios of methacrylic acid (MAA) were embedded in acrylamide hydrogels with a model drug, either sulforhodamine B or rhodamine 6G. Liposomes demonstrated the capacity to release their payload over 10 days while NIPAM nanogels and chitosan nanogels released within one or two days. We found that liposomes embedded in hydrogels presented two distinctive release mechanisms, a diffusive burst and a slower “sub-diffusive” release. Both nanogels on the other side presented no observable nor defined affinity-based release mechanism due to presence of salts, completely screening electrostatic interactions. The present work highlights critical points related to the release mechanisms from nanocomposite hydrogels as drug delivery devices or as biomedical tools for tissue engineering or regenerative medicine

Formulations nanoparticulaires dans les crèmes solaires : balance bénefique/risque et implication pour le conseil à l'officine

REIMS-BU Santé (514542104) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF

La vaccination par les aérosols : intérêts, concepts, applications éventuelles

REIMS-BU Santé (514542104) / SudocSudocFranceF

Mise en place de la Revue Qualité Produit au sein système d'assurance qualité d'une industrie pharmaceutique.Application à la production d'une forme gélule

REIMS-BU Santé (514542104) / SudocSudocFranceF

Etude comparative de l'intérêt et de la sécurité des adjuvants de formulation des déodorants et antitranspirants

REIMS-BU Santé (514542104) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF

Les méthodologies Lean et Six Sigma au service de l'amélioration de la performance : application à la production de sachets

REIMS-BU Santé (514542104) / SudocSudocFranceF

Syntèse de nanoparticules par le principe d'émulsification spontanée - diffusion de solvant

REIMS-BU Santé (514542104) / SudocSudocFranceF

Encapsulation de la céfépime dans des nanoparticules biocompatibles et biodégradables

REIMS-BU Santé (514542104) / SudocSudocFranceF